Why is elevation of serum cholesterol associated with exposure to perfluoroalkyl substances (PFAS) in humans? A workshop report on potential mechanisms
- PMID: 34246716
- PMCID: PMC9048712
- DOI: 10.1016/j.tox.2021.152845
Why is elevation of serum cholesterol associated with exposure to perfluoroalkyl substances (PFAS) in humans? A workshop report on potential mechanisms
Abstract
Serum concentrations of cholesterol are positively correlated with exposure to perfluorooctanoic acid (PFOA) and perfluorooctane sulfonic acid (PFOS) in humans. The associated change in cholesterol is small across a broad range of exposure to PFOA and PFOS. Animal studies generally have not indicated a mechanism that would account for the association in humans. The extent to which the relationship is causal is an open question. Nonetheless, the association is of particular importance because increased serum cholesterol has been considered as an endpoint to derive a point of departure in at least one recent risk assessment. To gain insight into potential mechanisms for the association, both causal and non-causal, an expert workshop was held Oct 31 and Nov 1, 2019 to discuss relevant data and propose new studies. In this report, we summarize the relevant background data, the discussion among the attendees, and their recommendations for further research.
Keywords: Fluorocarbons; Mechanism of action; Perfluoroalkyl substances; Serum cholesterol.
Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest
3M was not involved in the preparation of the manuscript. The authors retained sole control of the manuscript content and the findings, and statements in this paper are those of the authors and not those of the author’s employer or the sponsors. No authors were directly compensated by 3 M. This project was funded through a contract between 3 M and Ramboll, an international science and engineering company that provided salary compensation to the authors. None of the authors are currently engaged to testify as experts on behalf of the sponsors in litigation related to the compound discussed in this manuscript. Dr Fletcher has served in the past as a paid consultant to law firms conducting litigation involving PFAS, for both plaintiffs and defendants. The information in this document has been subjected to review by the Center for Public Health and Environmental Assessment, Office of Research and Development, EPA and approved for publication. Approval does not signify that the contents reflect the views of the Agency, nor does mention of trade names or commercial products constitute endorsement or recommendation for use.
Figures
References
-
- Andersen ME, Black MB, Pendse SN, Clewell RA, LeCluyse EL, McMullen PD, 2019. Zonal-specific transcriptional programs associated with PPARα activation in the rat liver and their role in liver cancer in rodents. Toxicologist 168, 232 (Abstract).
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
